Group announces that the Board of Directors has nominated Fabrice Chouraqui to become Pharming’s new Executive Director and ...

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General ...

Pharming to nominate Fabrice Chouraqui as new executive director and chief executive officer: Leiden, the Netherlands ...

Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after ...

Pharming Group (NASDAQ:PHAR) has nominated Fabrice Chouraqui as its new Executive Director and CEO, succeeding Sijmen de Vries. The appointment will be for a four-year term, subject to shareholder ...

The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company ...

Dutch biotech Pharming Group today announced that its board of directors has nominated Fabrice Chouraqui to become the ...

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST ...

Check the time stamp on this data. Updated AI-Generated Signals for Pharming Group N.v. (PHAR) available here: PHAR. Type a few symbols and Take a Trial. The signals for these will appear immediately ...

There is never a perfect time to do an interview, so carpe diem! It was a Monday morning; having managed to block the calendars of the Merchant family in Mumbai, I went up the thoroughfare to the ...

Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM).

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...